Literature DB >> 30300138

Correction: Repeated superovulation increases the risk of osteoporosis and cardiovascular diseases by accelerating ovarian aging in mice.

Jinjin Zhang1, Zhiwen Lai1,2, Liangyan Shi3, Yong Tian4, Aiyue Luo1, Zheyuan Xu1, Xiangyi Ma1, Shixuan Wang1.   

Abstract

Entities:  

Keywords:  correction

Year:  2018        PMID: 30300138      PMCID: PMC6188479          DOI: 10.18632/aging.101569

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


× No keyword cloud information.
Original article: Aging (Albany NY) 2017; 10: 1089-1102 This article has been corrected: The authors have submitted the wrong composite Figure 6 (D) which had employed SEM photographs of other group mice unintentionally. The corrected Figure 6 is provided below. The authors declare that this correction does not change the results or conclusions of this paper. The authors sincerely apologize for this error. Ultrastructural changes of the ovarian granulosa cells in both groups. (A-C) The normal ultrastructure in the ovaries of NC mice. Few lipids were observed in the ovaries, and most mitochondria structures were normal. (D-F) The mitochondria were swollen, exhibited decreased matrix density, and developed flocculent dense bodies in the matrix space in the RS group mice. The number of lipid droplets and swollen Golgi complexes were increased in RS group mice. (O: oocyte; N: nucleus of granulosa cells; M: mitochondrial; L: lipid; G: Golgi complex).
  2 in total

1.  The role of resveratrol in bone marrow-derived mesenchymal stem cells from patients with osteoporosis.

Authors:  Jing Li; Zhaoxu Xin; Mingjun Cai
Journal:  J Cell Biochem       Date:  2019-05-20       Impact factor: 4.429

2.  He's Yangchao Recipe Ameliorates Ovarian Oxidative Stress of Aging Mice under Consecutive Superovulation Involving JNK- And P53-Related Mechanism.

Authors:  Ying Zhao; Yun Chen; Chenyun Miao; Ruye Wang; Liuqing Yang; Jingjing Liu; Zhongfang Chen; Qin Zhang; Jing Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-08       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.